METHODS OF INHIBITING RECEPTOR TYROSINE KINASES WITH AN EXTRACELLULAR ANTAGONIST AND AN INTRACELLULAR ANTAGONIST
The present invention relates to methods of inhibiting receptor tyrosine kinases by utilizing a combination of both an extracellular and an intracellular RTK antagonist. The extracellular RTK antagonist is a biological molecule or a small molecule that inhibits activation of the receptor tyrosine kinase by interacting with the extracellular binding region of the receptor. The intracellular RTK antagonist is a biological molecule or small molecule that inhibits tyrosine kinase activity of the receptor tyrosine kinase by interacting with the receptor's intracellular region bearing a kinase domain or by interacting with an intracellular protein involved in the signaling pathway of the receptor tyrosine kinase. The present invention also provides methods of treating tyrosine kinase dependent diseases, and compositions for use in such methods thereof, by administering a combination of both an extracellular and an intracellular RTK antagonist.
1 . A method of inhibiting a receptor tyrosine kinase (RTK) in a mammal comprising administering an extracellular RTK antagonist and an intracellular RTK antagonists to the mammal.
2 . The method of claim 1 , wherein the method is used to treat a tumor growth or angiogenesis in the mammal.
3 . The method of claim 1 or 2 , wherein the RTK is Epidermal Growth Factor Receptor (EGFR).
4 . The method of claim 3 , wherein the extracellular RTK antagonist is cetuximab, ABX-EGF, EMD 72000, h-R3, or Y10.
5 . The method of claim 3 , wherein the intracellular RTK antagonist is ZD1939 or OSI-774.
6 . The method of claim 1 or 2 , wherein the RTK is HER2 receptor.
7 . The method of claim 6 , wherein the extracellular RTK antagonist is trastuzumab.
8 . The method of claim 1 or 2 , wherein the RTK is Vascular Endothelial Growth Factor Receptor (VEGFR).
9 . The method of claim 8 , wherein the extracellular RTK antagonist is bevacizumab.
10 . The method of claim 1 or 2 , wherein the intracellular RTK antagonist inhibits ras protein or a ras-raf modulator.
11 . The method of claim 1 or 2 , wherein the method further comprises administrating an antineoplastic agent.
12 . A pharmaceutical composition comprising an extracellular RTK antagonist and an intracellular RTK antagonist.
13 . The pharmaceutical composition of claim 12 , wherein the RTK is Epidermal Growth Factor Receptor (EGFR).
14 . The pharmaceutical composition of claim 13 , wherein the extracellular RTK antagonist is cetuximab, ABX-EGF, EMD 72000, h-R3, or Y10.
15 . The pharmaceutical composition of claim 13 or 14 , wherein the intracellular RTK antagonist is ZD1939 or OSI-774.
16 . The pharmaceutical composition of claim 12 , wherein the RTK is HER2 receptor.
17 . The pharmaceutical composition of claim 16 , wherein the extracellular RTK antagonist is trastuzumab.
18 . The pharmaceutical composition of claim 12 , wherein the RTK is Vascular Endothelial Growth Factor Receptor (VEGFR).
19 . The pharmaceutical composition of claim 18 , wherein the extracellular RTK antagonist is bevacizumab.
20 . The pharmaceutical composition of claim 12 , wherein the intracellular RTK antagonist inhibits ras protein or a ras-raf modulator.
21 . The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition further comprises an antineoplastic agent.